AR034866A1 - Comprimido que comprende cetirizina y pseudoefedrina - Google Patents
Comprimido que comprende cetirizina y pseudoefedrinaInfo
- Publication number
- AR034866A1 AR034866A1 ARP020102430A ARP020102430A AR034866A1 AR 034866 A1 AR034866 A1 AR 034866A1 AR P020102430 A ARP020102430 A AR P020102430A AR P020102430 A ARP020102430 A AR P020102430A AR 034866 A1 AR034866 A1 AR 034866A1
- Authority
- AR
- Argentina
- Prior art keywords
- tablet
- cetirizine
- pseudoephedrine
- active ingredient
- segments
- Prior art date
Links
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001803 cetirizine Drugs 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 3
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 3
- 229960003908 pseudoephedrine Drugs 0.000 abstract 3
- 201000009240 nasopharyngitis Diseases 0.000 abstract 2
- 206010041232 sneezing Diseases 0.000 abstract 2
- 206010015150 Erythema Diseases 0.000 abstract 1
- 206010052140 Eye pruritus Diseases 0.000 abstract 1
- 206010022004 Influenza like illness Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 206010052437 Nasal discomfort Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000036284 Rhinitis seasonal Diseases 0.000 abstract 1
- 208000036071 Rhinorrhea Diseases 0.000 abstract 1
- 206010039101 Rhinorrhoea Diseases 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un comprimido que comprende al menos dos segmentos distintos, un segmento de los cuales comprende como ingrediente activo principalmente cetirizina, y un segundo segmento que comprende como ingrediente activo principalmente pseudoefedrina, en donde los citados segmentos están compuestos y formados de tal manera que el comprimido resultante está sustancialmente exento de impurezas formadas mediante reacción de cetirizina con pseudoefedrina, y con la condición de que el comprimido comprende menos del 5% en peso, respecto del peso total del comprimido, de un agente alcalinizante. Además, dichos segmentos están compuestos y formados de tal manera que los perfiles farmacocinéticos de la cetirizina y la pseudoefedrina sean sustancialmente el mismo, como en una forma de administración que contenga cada uno como único ingrediente activo en la misma cantidad. Uso de un comprimido según lo descripto para la fabricación de un medicamento para prevenir o tratar trastornos o afecciones asociadas con rinitis, resfriado, gripe, síntomas de tipo resfriado o gripe y rinitis alérgica, alivio de congestión nasal, rinitis estacional, estornudos, rinorrea, prurito nasal y ocular, enrojecimiento de los ojos, lagrimeo y estornudos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30125001P | 2001-06-28 | 2001-06-28 | |
| EP01115807 | 2001-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034866A1 true AR034866A1 (es) | 2004-03-24 |
Family
ID=26076635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102430A AR034866A1 (es) | 2001-06-28 | 2002-06-28 | Comprimido que comprende cetirizina y pseudoefedrina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7014867B2 (es) |
| JP (1) | JP2007176958A (es) |
| KR (1) | KR20090029314A (es) |
| AR (1) | AR034866A1 (es) |
| BG (1) | BG66269B1 (es) |
| CO (1) | CO5540370A2 (es) |
| CR (1) | CR7198A (es) |
| CY (1) | CY1109238T1 (es) |
| DE (1) | DE60232445D1 (es) |
| HR (1) | HRP20031057B1 (es) |
| IL (1) | IL159287A0 (es) |
| MY (1) | MY129643A (es) |
| NO (1) | NO20035798L (es) |
| ZA (1) | ZA200309720B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2354688T3 (es) * | 2002-01-15 | 2011-03-17 | Ucb Farchim S.A. | Formulaciones para la administración oral de compuestos activos. |
| KR100754239B1 (ko) | 2005-04-29 | 2007-09-03 | 주식회사 서울제약 | 염산세티리진과 염산슈도에페드린을 함유하는 제어방출성의 경구용 제제 및 그의 제조방법 |
| WO2007141743A2 (en) * | 2006-06-06 | 2007-12-13 | Ranbaxy Laboratories Limited | A tablet dosage form comprising cetirizine and pseudoephedrine |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| US8962022B2 (en) * | 2007-03-27 | 2015-02-24 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family |
| CA2748728C (en) * | 2009-01-05 | 2017-01-03 | Mcneil-Ppc, Inc. | Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer |
| CA2748783A1 (en) * | 2009-01-05 | 2010-07-08 | Mcneil-Ppc, Inc. | Three layer tablet containing cetirizine, pseudoephedrine, and naproxen |
| US8252330B2 (en) * | 2009-01-05 | 2012-08-28 | Mcneil-Ppc, Inc. | Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen |
| WO2011078993A1 (en) * | 2009-12-21 | 2011-06-30 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
| KR101193495B1 (ko) * | 2010-02-01 | 2012-10-23 | 한미사이언스 주식회사 | 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물 |
| KR20130009553A (ko) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| JP2020015690A (ja) * | 2018-07-25 | 2020-01-30 | ニプロ株式会社 | レボセチリジン含有錠剤 |
| US11701350B2 (en) | 2019-07-22 | 2023-07-18 | L. Perrigo Company | Dextromethorphan extended release pharmaceutical composition |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783465A (en) | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| CA2087435C (en) | 1990-08-07 | 1998-05-05 | Scott Max Herbig | Use of interfacially-polymerized membranes in delivery devices |
| HUT75616A (en) | 1992-03-17 | 1997-05-28 | Pfizer | Method for prooucing porous delivery devices |
| CA2128820A1 (en) | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
| JPH11510168A (ja) | 1995-07-28 | 1999-09-07 | ザ、プロクター、エンド、ギャンブル、カンパニー | 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法 |
| US6469009B1 (en) | 1996-04-08 | 2002-10-22 | Ucb, S.A. | Pharmaceutical compositions for the treatment of rhinitis |
| EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| ATE421318T1 (de) * | 1997-02-20 | 2009-02-15 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| DE19716907A1 (de) | 1997-04-22 | 1998-11-05 | Siemens Ag | Regelung für ein Hochleistungsförderband im industriellen Einsatz |
| US6027746A (en) | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
| WO1999032125A1 (en) | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US6270790B1 (en) | 1998-08-18 | 2001-08-07 | Mxneil-Ppc, Inc. | Soft, convex shaped chewable tablets having reduced friability |
| US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6521254B2 (en) | 1998-12-07 | 2003-02-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6267986B1 (en) | 1999-09-24 | 2001-07-31 | Ranbaxy Laboratories Limited | Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine |
| EP1240897B1 (en) | 2001-03-14 | 2006-06-21 | Pfizer Products Inc. | Pharmaceutical tablet and process for making thereof |
| EP1241110A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
| US20030096791A1 (en) | 2001-05-31 | 2003-05-22 | Cima Labs Inc. | Taste masking of highly water-soluble drugs |
| RU2286784C2 (ru) * | 2001-06-28 | 2006-11-10 | ЮСиБи ФАРШИМ С.А. | Таблетка, содержащая цетиризин и псевдоэфедрин |
-
2002
- 2002-06-10 KR KR1020097004649A patent/KR20090029314A/ko not_active Ceased
- 2002-06-10 IL IL15928702A patent/IL159287A0/xx not_active IP Right Cessation
- 2002-06-10 DE DE60232445T patent/DE60232445D1/de not_active Expired - Lifetime
- 2002-06-10 US US10/481,264 patent/US7014867B2/en not_active Expired - Lifetime
- 2002-06-10 HR HRP20031057AA patent/HRP20031057B1/hr not_active IP Right Cessation
- 2002-06-26 MY MYPI20022397A patent/MY129643A/en unknown
- 2002-06-28 AR ARP020102430A patent/AR034866A1/es unknown
-
2003
- 2003-12-11 CR CR7198A patent/CR7198A/es not_active Application Discontinuation
- 2003-12-15 CO CO03109418A patent/CO5540370A2/es not_active Application Discontinuation
- 2003-12-15 ZA ZA2003/09720A patent/ZA200309720B/en unknown
- 2003-12-15 BG BG108452A patent/BG66269B1/bg unknown
- 2003-12-23 NO NO20035798A patent/NO20035798L/no not_active Application Discontinuation
-
2005
- 2005-10-18 US US11/251,895 patent/US7226614B2/en not_active Expired - Lifetime
-
2007
- 2007-03-30 JP JP2007092969A patent/JP2007176958A/ja active Pending
-
2009
- 2009-07-14 CY CY20091100745T patent/CY1109238T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007176958A (ja) | 2007-07-12 |
| US20040170690A1 (en) | 2004-09-02 |
| CY1109238T1 (el) | 2014-07-02 |
| KR20090029314A (ko) | 2009-03-20 |
| HRP20031057B1 (hr) | 2013-05-31 |
| MY129643A (en) | 2007-04-30 |
| US7014867B2 (en) | 2006-03-21 |
| CR7198A (es) | 2008-07-29 |
| BG66269B1 (bg) | 2012-11-30 |
| HK1064596A1 (en) | 2005-02-04 |
| IL159287A0 (en) | 2004-06-01 |
| US7226614B2 (en) | 2007-06-05 |
| CO5540370A2 (es) | 2005-07-29 |
| NO20035798L (no) | 2004-02-27 |
| BG108452A (en) | 2005-02-28 |
| US20060034928A1 (en) | 2006-02-16 |
| ZA200309720B (en) | 2005-02-23 |
| HRP20031057A2 (en) | 2005-10-31 |
| DE60232445D1 (de) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034866A1 (es) | Comprimido que comprende cetirizina y pseudoefedrina | |
| UY31430A1 (es) | Derivados de piridina y pirazina -83 | |
| EP1541151A4 (en) | TREATMENT AGAINST GLAUCOMA BASED ON RHO KINASE INHIBITORS AND PROSTAGLANDINS | |
| AR034619A1 (es) | Formulaciones de olopatadine para administracion topica | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| BRPI0411825B8 (pt) | inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| DE50211204D1 (de) | Cannabis extrakten pharmazeutische zusammensetzung | |
| DK1885336T3 (da) | Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser | |
| RU2010142353A (ru) | Водные фармацевтические композиции, содержащие борат-полиольные комплексы | |
| CA2454976A1 (en) | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient | |
| AR072805A1 (es) | Composiciones intranasales formas galenicas y metodos de tratamiento. | |
| CY1108676T1 (el) | Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων | |
| ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
| UY26992A1 (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| CO6251360A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| TW200603787A (en) | Topical preparations containing ambroxol | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| GR3019274T3 (en) | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |